Telling IPF from fibrotic hypersensitivity pneumonitis is notoriously tricky — but a novel breath test may change that. Researchers found that a single sphingolipid molecule in exhaled breath condensate correctly identified fibrotic hypersensitivity pneumonitis 80% of the time and IPF 85.7% of the time. The test is cheap, noninvasive, and could be ready for clinical use if validated in larger studies.
Telling IPF from fibrotic hypersensitivity pneumonitis is notoriously tricky — but a novel breath test may change that. Presented at the CHEST Annual Meeting in Phoenix, new research found that measuring sphingolipids in exhaled breath condensate (EBC) could reliably distinguish between two fibrotic lung diseases that often look nearly identical on imaging, pathology, and clinical presentation.
The key player? A single molecule — sphingomyelin C24:0 — found in exhaled breath. It correctly identified fibrotic hypersensitivity pneumonitis in 80% of cases and IPF in 85.7%, achieving an area under the ROC curve (AUC) of 0.897. A blood-based sphingolipid test performed more modestly (AUC 0.737) and added little when combined with the breath test (AUC 0.906), suggesting the breath test alone does most of the heavy lifting.
Lead researcher Dr. Jon Mullholand of Virginia Commonwealth University noted that getting the diagnosis wrong has real consequences — different treatments and different prognoses. While the test isn't yet widely available and still needs external validation, he's optimistic: "If we can verify the results, I think this could be quickly applied to clinical practice."
By the Numbers:
Why it matters: Misdiagnosing these two conditions leads to wrong treatments and worse outcomes. A cheap, noninvasive breath test that can tell them apart would be a significant step forward for pulmonologists — especially in community settings where advanced diagnostic tools are limited.
